Drug Pipeline

LY4268989 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
3
Recruiting
2
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-16 NCT06226883
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's…		 Trial sites expanded: 215 -> 226 locations
Active Studies by Phase
Phase 2
3
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06226883 A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's… Inflammatory Bowel Diseases Recruiting
NCT07186101 LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to… Ulcerative Colitis Recruiting
NCT07415044 LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis (UC) Recruiting
Sponsors Running LY4268989 Trials
Eli Lilly and Company (2) Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (1)
Disease Areas
Ulcerative Colitis (2) Crohn's Disease (1)
Get alerts when LY4268989 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free